Westmore · UDRP decision
CAC · Case No. CAC-UDRP-101950

Boehringer-ingeihelm.com

TransferCAC-indexed · informational, not legal advice

The Panel ordered transfer of the domain after finding it confusingly similar to the Complainant’s BOEHRINGER INGELHEIM marks, that the Respondent lacked rights or legitimate interests, and that the typo-form domain was registered and used in bad faith, including through passive holding and confusion-based attraction of Internet users.

Outcome
Transfer
At a glance
Provider
CAC
Outcome
Transfer
Decision date
2018-05-20
Panelist(s)
Mr. Jonathan Agmon
Complainant
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG
Respondent
boehringer-ingeihelm
Counsel
Enora Millocheau
Disputed domain(s)
boehringer-ingeihelm.com
Citation weightrelies on 10 authorities
Domain history UDRP Intelligence

The timeline behind boehringer-ingeihelm.com

Registration, the decision and the archived record of what this domain actually displayed — from public RDAP and the Internet Archive.

Reconstructing the record for boehringer-ingeihelm.com…
Verified public record
Outcome & remedy
Complaint granted. Panel ordered transfer of boehringer-ingeihelm.com.
Reverse Domain Name Hijacking
No RDNH raised.
Westmore Insight

Considering the totality of the circumstances, the Panel found bad-faith registration and use. The trademarks predated the domain, the mark was highly distinctive, the domain closely resembled the mark, the Respondent did not respond, and passive holding did not support any conceivable good-faith use. The Panel further found that the Respondent used the domain to attract Internet users by creating confusion as to source, affiliation, or endorsement under paragraph 4(b)(iv).

The three-part test
Identical or confusingly similarMet
Rights or legitimate interestsMet
Registered and used in bad faithMet

Result of record. The panel's reasoning and decisive facts behind each element are in the Intelligence dossier below.

Related decisions
Case details
Provider
CAC
Outcome
Transfer
Decision date
2018-05-20
Panel
Mr. Jonathan Agmon
Full decision
8 min read · hosted by Westmore

Case number CAC-UDRP-101950 Time of filing 2018-04-04 10:42:05 Domain names boehringer-ingeihelm.com Case administrator Organization Iveta Špiclová (Czech Arbitration Court) (Case admin) Complainant Organization BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Complainant representative Organization Nameshield (Enora Millocheau) Respondent Organization boehringer-ingeihelm Other Legal Proceedings The Panel is not aware of any other legal proceedings which are pending or decided and which relate to the disputed domain name. Identification Of Rights The Complainant is the owner of the following trademark registrations: - International Registration No. 221544 Boehringer-Ingelheim since July 2, 1959; - EU registration No. 000084657 Boehringer Ingelheim since September 21, 1998; and - US registration No. 2096339 Boehringer Ingelheim since September 19, 1997. The Complainant is a holder of the multiple domain names consisting of its' trademark in its entirety such as <Boehringer-Ingelheim.com>, <Boehringer-IngelheimGmbh.com>, <Boehringer-Ingelheim.jobs>, <Boehringer-Ingelheim.asia> and others. Factual Background The Complainant is a German family-owned pharmaceutical group of companies founded in 1885 in Ingelheim am Rhein. Today Boehringer is a global research enterprise, with 140 affiliated companies worldwide. Complainant contends that the Respondent is "typosquatting" in an attempt to benefit from it's trademark and reputation. It also argues that previous panels have found that the slight spelling variations does not prevent a disputed domain name from being confusingly similar to the complainant’s trademark. The disputed domain name is inactive and used as a parking webpage. The Complainant contends that it is not legitimate non-commercial or fair use of the disputed domain name. Given the distinctiveness of the Complainant's trademark and reputation, it is reasonable to infer that the Respondent has registered the domain name with full knowledge of the Complainant's trademarks. Parties Contentions NO ADMINISTRATIVELY COMPLIANT RESPONSE HAS BEEN FILED. Rights The Complainant has, to the satisfaction of the Panel, shown the disputed domain name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy). No Rights or Legitimate Interests The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the disputed domain name (within the meaning of paragraph 4(a)(ii) of the Policy). Bad Faith The Complainant has, to the satisfaction of the Panel, shown the disputed domain name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy). Procedural Factors The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision. Principal Reasons for the Decision A. Identical or Confusingly Similar Paragraph 4(a)(i) of the Policy requires the Complainant to show that the disputed domain name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights. A registered trademark provides a clear indication that the rights in the mark shown on the trademark certificate belong to its respective owner. The Complainant is the owner of trademarks registrations including: - International Registration No. 221544 Boehringer-Ingelheim since July 2, 1959; - EU registration No. 000084657 Boehringer Ingelheim since September 21, 1998; and - US registration No. 2096339 Boehringer Ingelheim since September 19, 1997. Previous Panels have found that domain name which consists of common, obvious misspelling, or a small variation such as inversion of a letter or two of a trademark, also called typo-squatting, will be found confusingly similar to the trademark (See WIPO Overview 3.0, paragraph 1.9; Schneider Electric S.A. v. Domain Whois Protect Service / Cyber Domain Services Pvt. Ltd. WIPO Case No. D2015-2333; Sanofi, Genzyme Corporation v. Domain Privacy WIPO Case No. D2016-1193). The disputed domain name <Boehringer-ingeilhelm.com> consists of a misspelled word of the complainant's registered trademark. In fact the difference between the Complainants' trademark and the disputed domain name is an inversion of the letter "L" and the letter "I". This inversion alongside the addition of the gTLD ".com", is not sufficient to escape the conclusion that the disputed domain name is confusingly similar to its' trademark. It is widely established that the addition of the gTLD “.com” to the disputed domain name does not avoid confusing similarity (see Accor v. Noldc Inc. WIPO Case No. D2005-0016; F. Hoffmann-La Roche AG v. Macalve e-dominios S.A., WIPO Case No. D2006-0451, and Telstra Corporation Limited v. Nuclear Marshmallows, WIPO Case No. D2000-0003; L’Oréal v Tina Smith, WIPO Case No. 2013-0820; Titoni AG v Runxin Wang, WIPO Case No. D2008-0820; and Alstom v. Itete Peru S.A. WIPO Case No. D2009-0877). Therefore, the gTLD “.com” is without significance in the present case since the use of a TLD is technically required to operate a domain name. Hence, the panel finds that the disputed domain name is confusingly similar to the Complainants' trademark. B. Rights or Legitimate Interests Once the Complainant establishes a prima facie case that the Respondent lacks rights or legitimate interests in the disputed domain name, the burden of production shifts to the Respondent to show that it has rights or legitimate interests in respect to the disputed domain name (see WIPO Overview of WIPO Panel Views on Selected UDRP Questions, Second Edition (“WIPO Overview 3.0”), paragraph 2.1). In the present case, the Complainant has demonstrated to the Panel that the Respondent lacks rights or legitimate interests in respect of the disputed domain name and the Respondent had failed to assert any such rights or legitimate interests. The Panel finds that the Complainant has established a prima facie case in this regard, inter alia, since the Complainant has not licensed or otherwise permitted the Respondent to use its "Boehringer Ingelheim" trademark, or a variation thereof. The Respondent is not commonly known by the disputed domain name. The Respondent has not submitted a response and did not provide any evidence to show any rights or legitimate interests in the disputed domain name that is sufficient to rebut the Complainant’s prima facie case. In the circumstances of this case and in light of the Respondent’s lack of use of the disputed domain name, as described above, the Panel finds that the Respondent has no rights or legitimate interests in respect of the disputed domain name. C. Registered and Used in Bad Faith The Complainant must show that the Respondent registered and is using the disputed domain name in bad faith (paragraph 4(a)(iii) of the Policy). Paragraph 4(b) of the Policy provides circumstances that may evidence bad faith under paragraph 4(a)(iii) of the Policy. The burden placed on the Complainant is to bring evidence showing circumstances that indicate that the Respondent registered and used the disputed domain name in bad faith. A Panel will look into the totality of the circumstances in each case, and these can include evidence of the degree of distinctiveness or reputation of the mark, the failure of the Respondent to file a response and the implausibility of any good faith use to which the domain name may be put. To show that the Respondent registered the disputed domain name in bad faith, the Complainant argued that the disputed domain name and the Complainant´s mark are similar, that the Respondent knew of the Respondent's trademark due to the Complainant's trademark and worldwide reputation and intended to take advantage of the Complainant's trademark. It emphasises that the misspelling of the trademark was intentional and designed to be confusingly similar to the trademark and is an indication to Respondents' bad faith. The Complainant has submitted evidence, which shows that the Respondent registered the disputed domain name long after the Complainant registered its trademarks. According to the evidence filed by the Complainant, the Complainant has owned the trademark since the year 1997. The Complainant's prior registered trademarks are suggestive of the respondent's bad faith (see Sanofi-Aventis v. Abigail Wallace, WIPO Case No. D2009-0735). In addition, while the disputed domain name is inactive, UDRP decisions have confirmed that the passive holding of a domain name coupled with other circumstances indicative of bad faith registration and use would suffice to establish the third element under the Policy (see, in this regard, Telstra Corporation Limited v. Nuclear Marshmallows, WIPO Case No. D2000-0003, Jupiters Limited v. Aaron Hall, WIPO Case No. D2000-0574). Therefore, the passive holding of the disputed domain name may be consistent with a finding of bad faith registration and use of both disputed domain name. In the present case, the apparent similarities between the Complainant's mark and the disputed domain name, and the fact that the Complainant's mark has a high degree of distinctiveness serve as additional evidence of bad faith registration and use of the disputed domain name. In the specific circumstances of this case, there is no conceivable use that the Respondent may make of the disputed domain name which would be in good faith. Considering these facts, including the absence of a Response and in view of the facts described above, the Panel finds that the Respondent has registered the disputed domain name in bad faith and has used the disputed domain name to attract Internet users on its website by creating a likelihood of confusion with the Complainant’s trademark as to source, affiliation or endorsement, in the meaning of paragraph 4(b)(iv) of the Policy, and thus acted in bad faith. For all the reasons stated above, the Complaint is Accepted and the disputed domain name(s) is (are) to be BOEHRINGER-INGEIHELM.COM: Transferred PANELLISTS Name Mr. Jonathan Agmon Date of Panel Decision 2018-05-20 Publish the Decision

Source of record: CAC . Reproduced for research; CAC is the authoritative source.

Beyond the decision

What Westmore sees around boehringer-ingeihelm.com

The decision is only the record. Westmore connects it to the cases, authorities, panelists, parties and domain evidence surrounding it.

Connected to Westmore UDRP Intelligence
115,966 decisions · citations · panelists · parties · domain history
Eleanor · UDRP intelligence
Ask Eleanor about this decision
Ask Eleanor about this decision

A short, grounded explanation drawn only from this decision's record — not legal advice or a prediction.

Unlocking Eleanor for this case uses 1 of your complimentary Intelligence unlocks· 3 remaining

Grounded in the Westmore record for this decision. Research/informational only — not legal advice or a prediction of any outcome.

Westmore Professional · Unlock the intelligence

The decision is only the beginning.

You've seen what happened. Now discover the deeper intelligence behind the case, the panelist, the parties and the authorities that matter.

Citation Intelligence
How this decision is cited and treated across the corpus.
Panelist Intelligence
The panel's tendencies, outcomes and reasoning patterns.
Domain History
Ownership chronology — creation vs. respondent acquisition.
Opposing-Party Research
Complainant, counsel and portfolio context.
Independent Case Review
Eleanor challenges your filing before the other side does.
Professional Matters
Open, research and manage matters end to end.
$395/month
Unlock Westmore Professional Annual & firm seats available · cancel anytime
Take the next step
Westmore UDRP · find the right service

Westmore UDRP records draw on CAC-indexed decisions and are provided for research and informational purposes only. Not legal advice, a clearance opinion, or a prediction of any outcome.

Confidential buyer-side representation for premium-domain acquisitions, backed by WHOIS, UDRP and domain-sales intelligence.

or
Buyer-side only Escrow-protected NDA on request
Services
Research
UDRP
Westmore
Support

Copyright © 2026 Westmore. All rights reserved.

Essential cookies only. Nothing is sold or shared.